<DOC>
	<DOCNO>NCT02569658</DOCNO>
	<brief_summary>To compare intravenous Tranexamic Acid ( TXA ) versus normal saline placebo determine whether TXA administration reduces blood loss , decrease hemoglobin , rate transfusion follow anatomic reverse total shoulder arthroplasty ( TSA ) surgery .</brief_summary>
	<brief_title>Investigation Intravenous Tranexamic Acid With Anatomic Reverse Total Shoulder Arthroplasty</brief_title>
	<detailed_description>Anatomic reverse total shoulder arthroplasty ( TSA ) associate risk moderate significant blood loss lead transfusion . Average estimate blood loss report range 354 361 mL intraoperatively , account additional postoperative blood loss postoperatively surgical drain . Transfusion rate report range 2.4 % 9.5 % recent study , rate 30 % revision case . Tranexamic acid ( TXA ) synthetic antifibrinolytic agent establish method reduce blood loss transfusion requirement patient undergoing total hip knee arthroplasty . TXA administer intravenously , topically ( intraarticularly ) , orally , available literature address intravenous topical administration . Systematic review meta-analyses total hip knee arthroplasty literature demonstrate approximately 30 % decrease blood loss 50 % decrease transfusion rate topical intravenous administration TXA compare placebo . Moreover , literature demonstrates increase rate thromboembolic complication associate TXA administration hip knee arthroplasty . Despite proven efficacy hip knee arthroplasty literature , study analyze ability TXA reduce blood loss transfusion rate follow TSA . Purpose study compare intravenous Tranexamic Acid ( TXA ) versus normal saline placebo determine whether TXA administration reduces blood loss , decrease hemoglobin , rate transfusion follow anatomic reverse total shoulder arthroplasty ( TSA ) surgery . With hypothesis intravenous TXA reduce blood loss follow TSA .</detailed_description>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Any patient schedule primary anatomic reverse TSA Allergy TXA Acquired disturbances color vision Preop use anticoagulant therapy within five day surgery History arterial venous thromboembolic disease ; DVT , PE , CVA , TIA Pregnancy breastfeed Recent MI ( within 6 month surgery ) placement stent regardless time since placement Renal impairment Refusal blood product Any patient undergoing revision TSA Patients decline participate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>